Upperton Pharma Solutions
Unit 11, Trent Gateway, Technology Dr, Beeston
Nottingham, NG9 1LA
UNITED KINGDOM
Visit Our Website
Visit Our Linkedin


Company Description

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture.

With over 25 years of experience, Upperton excels in rapid product introductions.

  • Our project delivery is unparalleled and designed specifically to align with the
    values and innovation of small to mid-sized pharma companies.
  • We are flexible and nimble, enabling rapid decision-making, problem-solving, collaboration, and product introduction within 4-6 weeks.
  • With subject matter experts and leadership team oversight on every project, you can trust our project delivery and expertise covers all layers of our operations.
  • For small molecules and biologics, our clinical manufacturing process trains support batch sizes from grams to kilograms.

Integrated CDMO Services

Experts in Oral, Nasal, Pulmonary & Sterile Dosage Forms

Upperton offers expertise in developing a range of small molecule and biologics dosage forms, providing support from early feasibility studies through to clinical and commercial manufacture.

  • Oral Solids: Upperton specialises in the development of both simple and complex oral dosage forms, including powders, capsules, and tablets (IR, MR, SR, Minitabs)
  • Nasal: Supporting both liquid and dry powder formulation, the development platform, UpperNose™, streamlines and accelerates the process of developing nasal dosage forms for clinical trial studies.
  • Pulmonary: Through expertise in formulation development, particle engineering and device selection. Upperton offers both dry powder and liquid formulation options, addressing factors such as solubility, stability, and target dose delivery into the lungs.
  • Sterile: Our team can support you with aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.

Our Capabilities at a Glance

  • Up to 1,000,000 tabletting capacity per day
  • 500g – 205kg blending capacity
  • Up to 2,000 blister packaging units per day
  • Up to 50kg tablet coating per batch
  • Up to 350,000 capsule filling (powder) capacity per day
  • Up to 1000kg dry granulation capacity per day
  • 0.5g – 10kg spray drying batch sizes (aqueous and solvent)
  • 20 litres solution preparation vessels capacity with overhead mixing
  • 10 state-of-the-art GMP manufacturing suites

Our Approach to Project Delivery

Upperton tailor’s projects to fit specific client timelines and requirements, prioritising effective communication and collaboration in project delivery. Each project is assigned a project manager who coordinates all activities and ensures that transparency is maintained through regular updates.

Project teams at Upperton are composed of experts from various disciplines, including development, GMP, analytical, QA, and technical transfer. The inclusion of an Executive Leadership Team member in every project, ensures that decisions are made under expert guidance.

Explore Our Resources

Videos

Discover Our Integrated CDMO Services

Whitepapers

Pharmaceutical Spray Drying: Technology & Applications 

Transitioning Your Product from Phase 1 To Phase 2 Clinical Studies 

Nose To Brain (N2B) Drug Delivery – Benefits & Challenges 

Nasal Delivery of Spray Dried Biologics: Opportunities & Challenges 

Spray Drying Biologics: An Alternative to Freeze Drying 

In Vivo Testing of Nasal Dosage Forms

Interactive Facility Tour

Facility Tour

Interactive Brochures

With You from Pre-Clinical to Market 

Your Sterile Partner of Choice


Webinars

Accelerating Nasal Dosage Form Development from Early-Phase to Clinical Trial Manufacture 

Use Of Spray Drying in Pharmaceutical Product Development 


Latest News

Upperton named Champion Award winner at CDMO Leadership Awards 2025 in Small Molecule Dosage Form category.

Upperton completes build of new £7m sterile manufacturing facility

Upperton Pharma Solutions Adds Large-Scale Processing following MHRA Approval at Nottingham Facility